Determination of SK&F 108566 (Teveten®) in human plasma by reversed-phase high-performance liquid chromatography

Determination of eprosartan in human plasma and urine by LC/MS/MS

“…So it needs to establish a highly sensitive and specific method to determine the drug concentration. Ferreiros et al [2,3] and Lundberg et al [4] use SPE to separate eprosartan from plasmatic interferences, which was time-consuming and complicated. Because of the sensitivity and specificity of LC/MS/MS, by the means of protein precipitation, the LLOQ of eprosartan in plasma was 5 ng/mL, which was enough for the determination of eprosartan in plasma and urine.…”

“…Ferreiros et al [2,3] and Lundberg et al [4] reported the limit of quantification of plasma eprosartan using SPE-HPLC-UV method to be 150 and 10 ng/mL, respectively. Hillaert et al [5][6][7] the determination of eprosartan using a capillary zone electrophoretic method.…”

Pharmacokinetics of intravenously and orally administered eprosartan in healthy males: absolute bioavailability and effect of food

“…Plasma samples were assayed for eprosartan concentrations using reversed-phase HPLC with UV detection [11]. The calibration curve was linear up to 5000 ng mL − 1 with a lower detection limit of 10 ng mL…”

Effect of Ranitidine on the Pharmacokinetics of Orally Administered Eprosartan, an Angiotensin II Antagonist, in Healthy Male Volunteers

“…10 Chromatographic separation was performed by use of reverse-phase HPLC, with a mixture of 50 mM citrate (pH 3.5) and tetrahydrofuran, 340:160 (v:v), as the mobile phase. Five hundred microliters of plasma was spiked with 25 µL of internal standard solution and 500 µL of 0.1M citrate buffer (pH 3.5) and briefly vortex-mixed.…”